TRIAL DATA
COMMIT Trial Compares Immunotherapy Alone to Chemo-Plus-Immunotherapy in dMMR Metastatic CRCThe COMMIT trial is a randomized study comparing atezolizumab alone versus mFOLFOX6/bevacizumab/atezolizumab as first-line treatment of deficient DNA mismatch repair metastatic colorectal cancer. (Journal of Clinical Oncology)